Treatment of Dementia-related Symptoms with Japanese Traditional Medicine (Kampo): A Review of Clinical Studies

@article{Okamoto2017TreatmentOD,
  title={Treatment of Dementia-related Symptoms with Japanese Traditional Medicine (Kampo): A Review of Clinical Studies},
  author={Hideki Okamoto},
  journal={Journal of Alzheimers Disease \& Parkinsonism},
  year={2017},
  volume={2017},
  pages={1-3}
}
  • H. Okamoto
  • Published 22 May 2017
  • Medicine
  • Journal of Alzheimers Disease & Parkinsonism
Japanese traditional medicine (Kampo) was the main medical treatment in Japan from the 6th century until Western medicine was introduced from Europe several hundred years ago, and it had been developed to treat all kinds of human diseases. Recently, Kampo has received renewed attention because it provides a valid alternative for treating symptoms refractory to modern conventional medicine. Some Kampo formulas have accumulated clinical evidence for their effectiveness, especially in… 
View via Publisher
1 Citations
Highly Influential Citations
1
Background Citations
1
Methods Citations
1

Tables from this paper

One Citation

Preventing Dementia Using Saffron, The Kampo Medicine, Kamiuntanto, and Their Combination, Kamiuntantokabankoka

Saffron and its major constituent, crocin were shown to enhance learning-memory, non-rapid eye movement (rem) sleep, and inhibit depression and neuronal cell death due to strong anti-oxidant and anti-inflammation activities.

References

SHOWING 1-10 OF 25 REFERENCES

Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions

Yonukan-san (Yi-Gan San in TCM), a Kampo formula that has been used empirically in Japan for more than 400 years, is examined, with the goal of clarifying its clinical indications.

A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia.

The present study suggests that TJ-54 is an effective and well-tolerated treatment for patients with BPSD and shows any effect on either cognitive function or ADL.

Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study.

Traditional Chinese medicine on four patients with Huntington's disease

Four Huntington's disease patients were treated with traditional Chinese medicines Yi‐Gan San (YGS) and Chaihu‐Jia‐Longgu‐Muli Tan (CLMT) in a cross‐over manner to suggest a possibility of a new treatment for involuntary movements.

Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae

It is suggested that orengedoku-to augmentation can be an effective option in cases that are partially responsive to yokukan-san treatment.

Reconsideration of Japanese traditional herbal medicine: new field of research and clinical medicine.

  • H. Okamoto
  • Medicine
    Mini reviews in medicinal chemistry
  • 2006
In order to safely and effectively apply Kampo, it is essential to understand oriental diagnostics, which is introduced, and current trends in Kampo research are reviewed.

Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-label study

Effects of the Traditional Chinese Herbal Medicine Yi-Gan San for Cholinesterase Inhibitor – Resistant Visual Hallucinations and Neuropsychiatric Symptoms in Patients With Dementia With Lewy Bodies

This study expanded on earlier observations on more generalized neuropsychiatric symptoms by using the Neuropsychiatric Inventory (NPI) and individual interviews to assess YGS treatment in a sample of patients who had cholinesterase inhibitor–resistant visual hallucinations and other symptoms of DLB.

Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease

Yi-Gan San for Treatment of Charles Bonnet Syndrome (Visual Hallucination Due to Vision Loss): An Open-Label Study

Yi-gan san may be an effective and safe therapy to control visual hallucination in patients with CBS and should be further tested in double-blind, placebo-controlled trials.